Individuals with a Dual Disorder (DD), namely a Severe Mental Illness (SMI) combined with substance misuse (or Substance Use Disorder (SUD) [
1]), present several challenges to clinicians and service providers. For one, although most psychiatric services typically offer mental health and substance misuse treatments apart, close to 50% of individuals with SMI are reported as having a DD [
2,
3]. In order to offer better treatments to people with DDs, integrated DD services have been developed whereby people with SMI can receive substance misuse treatment and mental health services under the same roof [
4]. Unfortunately, these specialized services are still scarce. Second, while mental disorders and alcohol or drug disorders are significantly interrelated, DDs are associated with increased severity and persistence of both disorders [
5]. Among the negative consequences of having a DD, we find higher rates of treatment non-compliance (including medication non-adherence), higher relapse rates, more severe psychotic symptoms, important cognitive deficits, depression and suicidal ideation, social withdrawal and alienation, housing instability or even homelessness, poor money management, increased risk for violence or being victimized, highest costs of care, as well as several physical ailments such as higher risks for hepatitis, HIV, heart, liver and
gastrointestinal diseases [
6,
7]. Furthermore, even when evidence-based treatments in psychiatric rehabilitation are offered, such as cognitive remediation treatments and supported employment services, people with DDs show lower success rates [
8].
Why should treating individuals with DDs be such a challenge? Recent studies suggest that in fact people with DDs might have much more complex clinical presentations than initially thought. For instance, a recent meta-analysis mentions that close to 70% of people with SMI have also experienced severe childhood trauma [
9]. Consistently, studies report higher rates of Post-traumatic
Stress Disorder (PTSD) in individuals with substance abuse as well as in individuals with SMIs, compared to the general population [
10,
11]. Additionally, traumatic events are also frequently reported in individuals with Cluster B personality disorders - 60 to 83% of adults diagnosed with borderline personality disorder report childhood abuse [
12]. According to Wickett et al. [
13], 59% of the individuals in their study with schizophrenia or
schizoaffective disorder presented with clinically significant Cluster B traits (histrionic, antisocial, borderline and narcissistic) and 24% endorsed items corresponding to a Cluster B personality disorder. Lysaker et al. [
14] found that 40% of individuals with schizophrenia in their sample also likely had a borderline personality disorder, which is linked to having higher risk of abusing substances [
15]. Furthermore, antisocial personality disorder is also quite prevalent in individuals with SMIsâ?? averaging 22% [
16], and is associated with substance abuse, housing instability, violence and trouble with the law [
17]. Noteworthy, DDs with borderline and antisocial personality traits are linked to childhood trauma, the former with sexual abuse and the latter with physical abuse [
14]. Lecomte et al. [
18] also found that people with persistent psychotic symptoms and methamphetamine misuse had high rates of trauma (91%, n=259), with 49% (n=139) of the sample meeting criteria for PTSD, as well as high rates of antisocial personality disorder (68%, n=152).
Besides personality disorders and PTSD, depressive symptoms are also quite common in individuals with DDs. Kamali et al. [
19] found that individuals with DDs who were hospitalized following a psychotic relapse reported significantly more suicidal ideation than past or non-substance users with psychosis. In a recent study by Lecomte et al. [
20] of individuals with psychosis and methamphetamine abuse, 43% (n=96) of the sample presented with persistent and severe depressive symptoms, predicted in part by their substance misuse as well as by trauma history. This study also revealed that psychotic and depressive symptoms were quite interrelated in individuals with DD linked to methamphetamine misuse [
20].
In this context, we define complex DDs as concomitant diagnoses of SMI (i. e. a psychotic disorder such as schizophrenia, schizo-affective disorder, etc.; or a mood disorder with psychotic features) and substance abuse, in addition to co-occuring personality disorders, as well as other comorbidities, such as depression, PTSD, anxiety, eating disorders, etc. Although the SMI and SUD must co-occur for the complex DD to be given, either the SMI or the SUD may have appeared first, and there is no time limit within which the second diagnosis must have appeared after the first one. Furthermore, we postulate that the observed shortcomings of DDs' treatments might be explained in part by the frequent presence of additional pathologies, which are typically not taken into consideration when developing or applying DDs treatments and case management protocols. These clusters of various psychopathologies reported in numerous studies suggest that, for individuals with complex DDs, current services focusing solely on psychotic symptoms and/or on substance misuse might only be partly helpful, as other co-occurring pathologies might make otherwise efficient therapeutic tools ineffective, as they are left untreated. Literature on the specific topic of complex DDs being scarce, little is known about what is actually happening in clinical settings dealing with these individuals. Investigating how people with such complex DDs, and clinicians working with them, both experience existing DDs treatments, from their respective perspectives, would foster insight into the development of more adaptive treatments. These experienced clinicians might have identified particular issues, dos and don'ts and other practical considerations, as well as perceptions of what is missing in currently applied treatment strategies and of what works best when treating service users diagnosed with complex DDs. Additionally, service users can from their perspective share which treatment experiences they felt made a difference, their perceived misses or unaddressed issues, how they feel treatments should be implemented in order to be more efficient, and so forth. Given the complexity regarding the treatment of service users with complex DDs, such information is needed prior to considering changing or offering novel services for this clientele. Given its potential to help clinicians develop novel services for people diagnosed with complex DDs, this study might bring on multiple clinical benefits such as improvement of psychotic symptoms management, treatment compliance, social inclusion, physical health, development of various protective factors, to name a few.